BGNE BeiGene, Ltd. Stock Quote

BGNE [NASD]

Index	-	P/E	-	EPS (ttm)	-21.27	Insider Own	20.60%	Shs Outstand	90.90M	Perf Week	-8.84%
Market Cap	30.49B	Forward P/E	-	EPS next Y	-14.47	Insider Trans	-9.29%	Shs Float	63.65M	Perf Month	-0.22%
Income	-1575.60M	PEG	-	EPS next Q	-4.81	Inst Own	62.20%	Short Float	3.46%	Perf Quarter	24.91%
Sales	265.70M	P/S	114.74	EPS this Y	-13.80%	Inst Trans	-0.15%	Short Ratio	4.82	Perf Half Y	28.38%
Book/sh	42.57	P/B	7.52	EPS next Y	18.80%	ROA	-33.40%	Target Price	314.02	Perf Year	106.46%
Cash/sh	48.82	P/C	6.56	EPS next 5Y	24.00%	ROE	-47.30%	52W Range	118.55 - 388.97	Perf YTD	23.84%
Dividend	-	P/FCF	-	EPS past 5Y	-60.30%	ROI	-37.50%	52W High	-17.73%	Beta	0.87
Dividend %	-	Quick Ratio	4.50	Sales past 5Y	103.70%	Gross Margin	74.60%	52W Low	169.93%	ATR	17.34
Employees	5300	Current Ratio	4.60	Sales Q/Q	75.90%	Oper. Margin	-	RSI (14)	41.40	Volatility	5.69% 4.36%
Optionable	Yes	Debt/Eq	0.13	EPS Q/Q	29.50%	Profit Margin	-	Rel Volume	0.87	Prev Close	329.73
Shortable	Yes	LT Debt/Eq	0.05	Earnings	-	Payout	-	Avg Volume	457.32K	Price	320.00
Recom	2.20	SMA20	-9.56%	SMA50	1.47%	SMA200	25.10%	Volume	397,203	Change	-2.95%

Nov-09-20

Downgrade

Ladenburg Thalmann

Buy → Neutral

Nov-06-20

Downgrade

Piper Sandler

Neutral → Underweight

$175 → $185

Nov-06-20

Downgrade

Maxim Group

Buy → Hold

Jul-10-20

Downgrade

CLSA

Buy → Outperform

Mar-13-20

Upgrade

Macquarie

Underperform → Neutral

Feb-18-20

Resumed

Goldman

Buy

Jan-17-20

Upgrade

CLSA

Outperform → Buy

Jan-17-20

Resumed

Morgan Stanley

Overweight

$210

Dec-16-19

Downgrade

Piper Jaffray

Overweight → Neutral

Dec-16-19

Downgrade

Guggenheim

Buy → Neutral

Nov-19-19

Downgrade

UBS

Buy → Neutral

Nov-13-19

Downgrade

CLSA

Buy → Outperform

Nov-04-19

Reiterated

Maxim Group

Buy

$170 → $210

Jun-04-19

Initiated

Bernstein

Outperform

$201

May-10-19

Upgrade

CLSA

Outperform → Buy

Mar-15-19

Initiated

BofA/Merrill

Buy

$200

Jan-04-19

Downgrade

CLSA

Buy → Outperform

Nov-21-18

Initiated

JP Morgan

Overweight

$174

Sep-25-18

Initiated

Leerink Partners

Outperform

May-17-18

Reiterated

Maxim Group

Buy

$200 → $225

Feb-27-21 01:21AM	BeiGene, Ltd. (NASDAQ:BGNE) Analysts Just Slashed This Year's Revenue Estimates By 33% Simply Wall St.
Feb-26-21 07:00AM	BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan Business Wire
06:41AM	Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy Benzinga
Feb-25-21 04:05PM	BeiGene Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire
Feb-17-21 05:00PM	Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists Business Wire -6.44%
09:33AM	BeiGene's US Application For BRUKINSA In A Type Of Lymphoma, Accepted For Review Benzinga
07:00AM	BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenströms Macroglobulinemia Business Wire
Jan-27-21 05:45PM	BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma Business Wire -10.50%
Jan-26-21 10:01PM	Novartis (NVS) Q4 2020 Earnings Call Transcript Motley Fool
Jan-23-21 01:52AM	Do Institutions Own BeiGene, Ltd. (NASDAQ:BGNE) Shares? Simply Wall St.
Jan-15-21 09:34AM	BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China Zacks
Jan-14-21 04:35PM	Beigene Stock Breaks Out To Record High On Cancer Drug OK In China Investor's Business Daily +8.33%
Jan-13-21 11:00PM	China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer Business Wire +7.34%
Jan-12-21 04:31PM	Beigene Surges Closer To Breakout On $2.2 Billion Deal With Novartis Investor's Business Daily
02:58PM	Novartis (NVS) In-Licenses Anti-PD-1 Antibody from BeiGene Zacks
08:15AM	The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue Benzinga
Jan-11-21 04:30PM	BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab Business Wire
07:00AM	Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strands Next-Generation, Multi-Functional mRNA Technology Business Wire
Jan-07-21 07:00AM	BeiGene to Present at the J.P. Morgan 39th Annual Healthcare Conference Business Wire
Dec-27-20 11:00PM	BeiGene Announces Inclusion of Three Innovative Oncology Products in China National Reimbursement Drug List (NRDL) Business Wire
Dec-14-20 09:10PM	Is BGNE A Good Stock To Buy Now? Insider Monkey
Dec-11-20 06:17PM	Hudson Executive Reports Cardtronics Stake Barrons.com
Dec-07-20 07:00PM	BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) Business Wire
10:00AM	BeiGene Presents Clinical Data on BRUKINSA® (Zanubrutinib) in B-Cell Malignancies and Waldenströms Macroglobulinemia at the 62nd ASH Annual Meeting Business Wire
Dec-06-20 12:30PM	BeiGene Announces Data on BRUKINSA® (Zanubrutinib) from Phase 2 Trial in Marginal Zone Lymphoma and Phase 3 Trial in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 62nd ASH Annual Meeting Business Wire
Dec-01-20 11:00PM	BeiGene Announces Pricing of Public Offering by Selling Shareholders Business Wire
04:15PM	BeiGene Launches Proposed Public Offering by Selling Shareholders Business Wire
Nov-23-20 07:00AM	BeiGene to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference Business Wire
Nov-20-20 07:37AM	The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga
Nov-19-20 08:00PM	BeiGene Announces the Approval of XGEVA® (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors and in Patients With Multiple Myeloma Business Wire
Nov-17-20 07:00AM	BeiGene Announces that RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met the Primary Endpoint of Overall Survival at Interim Analysis Business Wire
Nov-07-20 08:04AM	US$260 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:BGNE) Is Worth After These Results Simply Wall St.
Nov-05-20 04:05PM	BeiGene Reports Third Quarter 2020 Financial Results Business Wire
09:00AM	BeiGene Announces Data on BRUKINSA® (Zanubrutinib) and Tislelizumab to Be Presented at the 62nd ASH Annual Meeting Business Wire
Oct-09-20 07:05AM	How Should Investors React To BeiGene's (NASDAQ:BGNE) CEO Pay? Simply Wall St.
Oct-06-20 07:00AM	BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071 Business Wire
Oct-01-20 12:00PM	All You Need to Know About BeiGene, Ltd. (BGNE) Rating Upgrade to Buy Zacks
08:15AM	BeiGene's Shares March Higher, Can It Continue? Zacks
Sep-27-20 06:12AM	3 Top Biotech Stocks to Buy Right Now Motley Fool
Sep-21-20 07:00AM	Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer PR Newswire
Sep-17-20 06:05PM	BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer Business Wire
Sep-10-20 09:00AM	BeiGene to Present at the Morgan Stanley 18th Annual Global Healthcare Conference Business Wire
Sep-09-20 07:00AM	BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenströms Macroglobulinemia Business Wire
Sep-04-20 09:15AM	BeiGene Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs Business Wire
Aug-27-20 08:02AM	The Daily Biotech Pulse: Liver Congress Underway, FDA Approves Companion Diagnostic Test For Clovis Cancer Drug, EUA For Abbott's $5, 15-Minute COVID-19 Test Benzinga
07:00AM	BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals Business Wire
Aug-25-20 07:00AM	BeiGene Appoints Corsee Sanders, Ph.D. to its Board of Directors Business Wire +5.67%
Aug-24-20 08:08AM	Bio-Thera Solutions and BeiGene Announce License, Distribution, and Supply Agreement for Avastin® (Bevacizumab) Biosimilar BAT1706 in China Business Wire
Aug-07-20 12:00PM	What Makes BeiGene, Ltd. (BGNE) a New Buy Stock Zacks
Aug-06-20 04:05PM	BeiGene Reports Second Quarter 2020 Financial Results GlobeNewswire
Aug-05-20 07:00AM	BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress GlobeNewswire
Jul-27-20 09:15AM	Priority Review Granted to BeiGenes New Drug Application of Pamiparib in Ovarian Cancer in China GlobeNewswire
Jul-24-20 06:12PM	13Ds Filings Barrons.com
Jul-20-20 07:53AM	BeiGene, Assembly Bio Ink $540M China HBV Deal; Shares Surge In Pre-Market SmarterAnalyst
06:30AM	Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assemblys Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection GlobeNewswire
Jul-17-20 09:00AM	BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China GlobeNewswire +7.38%
Jul-16-20 10:31AM	Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More Zacks
Jul-15-20 05:00PM	BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering GlobeNewswire
04:19AM	Hillhouse Plans to Invest $1 Billion In Beigenes Share Sale Bloomberg
Jul-14-20 03:43PM	Why BeiGene Stock Jumped Today Motley Fool +11.24%
08:43AM	BeiGene (BGNE) in Focus: Stock Moves 8.7% Higher Zacks
Jul-13-20 10:51AM	Why BeiGene's Stock Is Trading Higher Today Benzinga +8.66%
10:11AM	Amgen (AMGN) Invests Further in China-Based Oncology Partner Zacks
07:53AM	Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money Simply Wall St.
06:40AM	Amgen Pours A Further $421M Into Chinas BeiGene SmarterAnalyst
02:03AM	BeiGene Plans $2B Direct Offering; Analyst Sees Further Upside Ahead SmarterAnalyst
Jul-12-20 09:30PM	Chinese Biotech Beigene to Raise $2.1 Billion in Share Sale Bloomberg
08:00PM	BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering GlobeNewswire
Jul-10-20 11:11AM	Insiders Roundup: Mastercard, Eli Lilly GuruFocus.com
Jul-05-20 04:04PM	Is BeiGene, Ltd. (BGNE) A Good Stock To Buy? Insider Monkey
Jul-02-20 07:00AM	BeiGene to Host Investor Conference Call and Webcast to Discuss the Companys Early Development Pipeline and Research GlobeNewswire
Jul-01-20 06:00PM	BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China GlobeNewswire
08:12AM	The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes Benzinga
07:00AM	BeiGene Announces Appointment of Angus Grant as Chief Business Executive GlobeNewswire
Jun-30-20 07:30PM	BeiGene Begins Commercializing XGEVA® (Denosumab) in China GlobeNewswire
Jun-22-20 09:00AM	BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial GlobeNewswire
Jun-19-20 12:27AM	BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China GlobeNewswire
Jun-18-20 07:30AM	BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenströms Macroglobulinemia GlobeNewswire
Jun-12-20 02:30AM	BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Association (EHA) Virtual Congress GlobeNewswire
Jun-05-20 07:30AM	BeiGene to Present at the Goldman Sachs 41st Annual Global Healthcare Conference GlobeNewswire
Jun-03-20 07:15AM	BeiGene Announces the Approval of BRUKINSA (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma GlobeNewswire
May-29-20 08:00AM	BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenströms Macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program GlobeNewswire
08:00AM	BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program GlobeNewswire
May-26-20 04:05PM	BeiGene to Host Investor Conference Call and Webcast to Discuss Clinical Study Results Presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program GlobeNewswire
04:04AM	Chi-Med, BeiGene Join Forces For Solid Cancer Tumor Treatment SmarterAnalyst
02:00AM	Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab GlobeNewswire
May-21-20 07:00AM	BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Application for BTK Inhibitor BRUKINSA (zanubrutinib) in Israel GlobeNewswire
May-20-20 07:00AM	BeiGene to Present at the Bernstein 36th Annual Strategic Decisions Conference GlobeNewswire
May-15-20 07:00AM	BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II GlobeNewswire
May-14-20 05:45PM	Growth Stocks Like Amazon And Tesla Share These Key Metrics: Advisor Investor's Business Daily
09:00AM	BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress GlobeNewswire
May-11-20 04:05PM	BeiGene Reports First Quarter 2020 Financial Results GlobeNewswire
Apr-29-20 05:00PM	BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
Apr-20-20 04:05PM	BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China GlobeNewswire
Apr-13-20 04:05PM	BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis GlobeNewswire
Apr-10-20 06:00PM	China National Medical Products Administration Approves BeiGenes Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma GlobeNewswire
Mar-26-20 02:30PM	ROSEN, A HIGHLY RANKED FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. Business Wire
Mar-25-20 09:00AM	BeiGene Announces Supply Update for ABRAXANE® in China GlobeNewswire -5.75%
Mar-19-20 05:09PM	Hedge Funds Are Betting On BeiGene, Ltd. (BGNE) Insider Monkey
Mar-10-20 12:57PM	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People's Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; Hutchison China MediTech Limited; and Novartis. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People's Republic of China.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Huang Jane	CMO, Hematology	Jan 29	Option Exercise	29.49	1,500	44,235	1,500	Feb 02 04:49 PM
Huang Jane	CMO, Hematology	Jan 29	Sale	322.99	1,500	484,492	0	Feb 02 04:49 PM
Liang Howard	CFO & Chief Strategy Officer	Jan 15	Option Exercise	6.50	12,600	81,900	12,600	Jan 19 05:04 PM
Liang Howard	CFO & Chief Strategy Officer	Jan 15	Sale	344.90	12,600	4,345,689	0	Jan 19 05:04 PM
Liang Howard	CFO & Chief Strategy Officer	Jan 14	Option Exercise	6.50	1,400	9,100	1,400	Jan 19 05:04 PM
Liang Howard	CFO & Chief Strategy Officer	Jan 14	Sale	344.47	1,400	482,256	0	Jan 19 05:04 PM
BAKER BROS. ADVISORS LP	Director	Jan 04	Sale	220.50	121,154	26,714,457	968,943	Jan 06 06:32 PM
Huang Jane	CMO, Hematology	Dec 29	Option Exercise	29.49	1,500	44,235	1,500	Dec 30 04:34 PM
Huang Jane	CMO, Hematology	Dec 29	Sale	249.13	1,500	373,690	0	Dec 30 04:34 PM
Liang Howard	CFO & Chief Strategy Officer	Dec 14	Option Exercise	0.87	1,497,200	1,300,000	1,573,715	Dec 16 04:43 PM
Liang Howard	CFO & Chief Strategy Officer	Dec 14	Sale	229.04	91,900	21,048,454	0	Dec 16 04:43 PM
BAKER BROS. ADVISORS LP	Director	Dec 04	Sale	220.50	1,511,546	333,295,893	979,003	Dec 04 05:24 PM
Huang Jane	CMO, Hematology	Nov 30	Option Exercise	29.49	1,500	44,235	1,500	Dec 02 05:01 PM
Huang Jane	CMO, Hematology	Nov 30	Sale	267.82	1,500	401,723	0	Dec 02 05:01 PM
Huang Jane	CMO, Hematology	Oct 29	Option Exercise	29.49	1,500	44,235	1,500	Nov 02 04:44 PM
Huang Jane	CMO, Hematology	Oct 29	Sale	300.06	1,500	450,093	0	Nov 02 04:44 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Oct 16	Sale	320.00	5,000	1,600,000	0	Oct 20 04:44 PM
Liang Howard	CFO & Chief Strategy Officer	Oct 05	Option Exercise	6.50	14,000	91,000	14,000	Oct 07 04:50 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Oct 05	Sale	300.00	5,000	1,500,000	0	Oct 07 04:56 PM
Wu Xiaobin	President & GM China	Oct 05	Sale	300.00	4,000	1,200,000	0	Oct 07 04:52 PM
Liang Howard	CFO & Chief Strategy Officer	Oct 05	Sale	299.60	14,000	4,194,413	0	Oct 07 04:50 PM
Huang Jane	CMO, Hematology	Sep 29	Option Exercise	29.49	1,500	44,235	1,500	Oct 01 04:52 PM
Huang Jane	CMO, Hematology	Sep 29	Sale	280.38	1,500	420,568	0	Oct 01 04:52 PM
OYLER JOHN	Chief Executive Officer	Sep 29	Sale	280.82	23,303	6,544,030	0	Sep 30 04:53 PM
OYLER JOHN	Chief Executive Officer	Sep 28	Sale	280.07	31,000	8,682,063	0	Sep 30 04:53 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Sep 25	Sale	280.42	5,000	1,402,116	0	Sep 29 04:59 PM
Wu Xiaobin	President & GM China	Sep 25	Sale	280.35	4,000	1,121,406	0	Sep 29 04:57 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Sep 17	Sale	260.27	5,000	1,301,356	0	Sep 21 04:53 PM
Wu Xiaobin	President & GM China	Sep 17	Sale	260.33	4,000	1,041,327	0	Sep 21 04:50 PM
OYLER JOHN	Chief Executive Officer	Sep 16	Sale	254.77	27,275	6,948,807	0	Sep 16 05:12 PM
OYLER JOHN	Chief Executive Officer	Sep 15	Sale	254.26	34,214	8,699,381	0	Sep 16 05:12 PM
Liang Howard	CFO & Chief Strategy Officer	Sep 14	Option Exercise	6.50	14,000	91,000	14,000	Sep 16 05:10 PM
OYLER JOHN	Chief Executive Officer	Sep 14	Sale	250.25	19,739	4,939,782	0	Sep 16 05:12 PM
Liang Howard	CFO & Chief Strategy Officer	Sep 14	Sale	250.27	14,000	3,503,764	0	Sep 16 05:10 PM
Huang Jane	CMO, Hematology	Sep 03	Sale	233.07	3,128	729,045	0	Sep 08 04:44 PM
OYLER JOHN	Chief Executive Officer	Sep 02	Sale	229.22	27,807	6,374,024	0	Sep 02 05:44 PM
OYLER JOHN	Chief Executive Officer	Sep 01	Sale	233.79	20,274	4,739,809	0	Sep 02 05:44 PM
OYLER JOHN	Chief Executive Officer	Aug 31	Sale	240.86	12,961	3,121,765	0	Sep 02 05:44 PM
Huang Jane	CMO, Hematology	Aug 28	Option Exercise	29.49	3,000	88,470	3,000	Sep 01 04:41 PM
Huang Jane	CMO, Hematology	Aug 28	Sale	242.21	3,000	726,626	0	Sep 01 04:41 PM
OYLER JOHN	Chief Executive Officer	Aug 21	Sale	240.19	40,788	9,796,775	0	Aug 21 05:21 PM
OYLER JOHN	Chief Executive Officer	Aug 20	Sale	234.62	21,523	5,049,749	0	Aug 21 05:21 PM
OYLER JOHN	Chief Executive Officer	Aug 19	Sale	234.56	29,866	7,005,265	0	Aug 21 05:21 PM
OYLER JOHN	Chief Executive Officer	Aug 14	Sale	211.15	8,705	1,838,034	0	Aug 14 05:30 PM
OYLER JOHN	Chief Executive Officer	Aug 13	Sale	214.48	14,443	3,097,762	0	Aug 14 05:30 PM
Chen Timothy Yung-Cheng	Director	Aug 12	Option Exercise	31.59	2,897	91,516	2,897	Aug 12 05:02 PM
OYLER JOHN	Chief Executive Officer	Aug 12	Sale	212.10	19,820	4,203,766	0	Aug 14 05:30 PM
Chen Timothy Yung-Cheng	Director	Aug 12	Sale	212.00	2,897	614,165	0	Aug 12 05:02 PM
Chen Timothy Yung-Cheng	Director	Aug 11	Option Exercise	31.59	1,903	60,116	1,903	Aug 12 05:02 PM
Chen Timothy Yung-Cheng	Director	Aug 11	Sale	213.04	1,903	405,409	0	Aug 12 05:02 PM
Chen Timothy Yung-Cheng	Director	Aug 10	Option Exercise	31.59	2,200	69,498	2,200	Aug 12 05:02 PM
Chen Timothy Yung-Cheng	Director	Aug 10	Sale	214.04	2,200	470,886	0	Aug 12 05:02 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Aug 10	Sale	211.06	4,000	844,229	0	Aug 12 04:38 PM
OYLER JOHN	Chief Executive Officer	Aug 05	Sale	223.27	17,254	3,852,273	0	Aug 05 05:43 PM
OYLER JOHN	Chief Executive Officer	Aug 04	Sale	220.43	15,383	3,390,951	0	Aug 05 05:30 PM
OYLER JOHN	Chief Executive Officer	Aug 03	Sale	221.78	25,176	5,583,575	0	Aug 05 05:30 PM
Huang Jane	CMO, Hematology	Jul 29	Option Exercise	94.95	3,000	284,835	3,000	Jul 31 04:24 PM
Huang Jane	CMO, Hematology	Jul 29	Sale	209.93	3,000	629,787	0	Jul 31 04:24 PM
OYLER JOHN	Chief Executive Officer	Jul 22	Sale	238.34	27,748	6,613,503	0	Jul 22 06:22 PM
OYLER JOHN	Chief Executive Officer	Jul 21	Sale	251.83	26,413	6,651,695	0	Jul 22 06:14 PM
OYLER JOHN	Chief Executive Officer	Jul 20	Sale	251.85	28,762	7,243,784	0	Jul 22 06:14 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jul 20	Sale	251.31	12,000	3,015,740	0	Jul 22 04:47 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jul 20	Sale	251.98	5,000	1,259,896	0	Jul 22 04:47 PM
Wu Xiaobin	President & GM China	Jul 20	Sale	250.16	2,600	650,407	0	Jul 21 04:50 PM
Wu Xiaobin	President & GM China	Jul 17	Sale	245.74	700	172,015	0	Jul 21 04:50 PM
Wu Xiaobin	President & GM China	Jul 15	Sale	241.11	2,700	650,998	0	Jul 15 05:14 PM
Wu Xiaobin	President & GM China	Jul 13	Sale	220.00	3,000	660,000	0	Jul 15 05:14 PM
OYLER JOHN	Chief Executive Officer	Jul 08	Sale	201.39	17,529	3,530,206	0	Jul 08 05:20 PM
Huang Jane	CMO, Hematology	Jul 07	Option Exercise	160.40	3,921	628,928	3,921	Jul 09 04:43 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jul 07	Sale	200.00	6,000	1,200,000	0	Jul 09 04:45 PM
Huang Jane	CMO, Hematology	Jul 07	Sale	200.00	3,921	784,200	0	Jul 09 04:43 PM
OYLER JOHN	Chief Executive Officer	Jul 07	Sale	198.86	19,023	3,782,987	0	Jul 08 05:20 PM
OYLER JOHN	Chief Executive Officer	Jul 06	Sale	197.11	17,362	3,422,262	0	Jul 08 05:20 PM
OYLER JOHN	Chief Executive Officer	Jul 01	Sale	191.57	3,816	731,016	0	Jul 01 04:43 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jul 01	Sale	190.75	4,847	924,572	0	Jul 06 04:52 PM
Huang Jane	CMO, Hematology	Jun 29	Option Exercise	29.49	1,500	44,235	1,500	Jun 30 04:14 PM
OYLER JOHN	Chief Executive Officer	Jun 29	Sale	192.60	1,435	276,374	0	Jul 01 04:43 PM
Liang Howard	CFO & Chief Strategy Officer	Jun 29	Sale	191.23	300	57,368	0	Jul 01 04:38 PM
Huang Jane	CMO, Hematology	Jun 29	Sale	190.83	1,935	369,250	0	Jun 30 04:14 PM
Huang Jane	CMO, Hematology	Jun 26	Option Exercise	160.40	2,079	333,472	2,079	Jun 30 04:14 PM
Huang Jane	CMO, Hematology	Jun 26	Sale	200.29	2,079	416,397	0	Jun 30 04:14 PM
OYLER JOHN	Chief Executive Officer	Jun 24	Sale	187.34	14,381	2,694,156	0	Jun 24 08:23 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jun 23	Sale	186.38	6,000	1,118,298	0	Jun 24 08:12 PM
OYLER JOHN	Chief Executive Officer	Jun 23	Sale	186.88	15,070	2,816,222	14,381	Jun 24 08:23 PM
OYLER JOHN	Chief Executive Officer	Jun 22	Sale	182.43	10,281	1,875,605	29,451	Jun 24 08:23 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jun 22	Sale	181.33	5,000	906,673	0	Jun 24 08:12 PM
OYLER JOHN	Chief Executive Officer	Jun 10	Sale	175.07	900	157,563	0	Jun 12 04:14 PM
Liang Howard	CFO & Chief Strategy Officer	Jun 08	Sale	170.84	453	77,391	0	Jun 10 05:17 PM
Wu Xiaobin	President & GM China	Jun 08	Sale	170.83	2,800	478,317	0	Jun 10 05:15 PM
Huang Jane	CMO, Hematology	Jun 08	Sale	170.84	631	107,800	0	Jun 10 05:13 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jun 08	Sale	170.91	6,000	1,025,455	0	Jun 10 05:12 PM
Huang Jane	CMO, Hematology	May 29	Option Exercise	29.49	1,500	44,235	1,500	Jun 02 04:11 PM
Huang Jane	CMO, Hematology	May 29	Sale	163.86	1,500	245,784	0	Jun 02 04:11 PM
Glazer Donald W.	Director	May 19	Sale	169.84	10,000	1,698,400	0	May 21 04:08 PM
OYLER JOHN	Chief Executive Officer	May 01	Sale	141.43	4,635	655,537	0	May 05 04:48 PM
Wu Xiaobin	President & GM China	May 01	Sale	141.33	7,024	992,711	0	May 05 04:46 PM
Huang Jane	CMO, Hematology	Apr 29	Option Exercise	29.49	1,500	44,235	1,500	Apr 30 04:04 PM
Huang Jane	CMO, Hematology	Apr 29	Sale	162.30	1,500	243,450	0	Apr 30 04:04 PM
Huang Jane	CMO, Hematology	Apr 16	Option Exercise	29.49	1,500	44,235	1,500	Apr 17 04:04 PM
Huang Jane	CMO, Hematology	Apr 16	Sale	160.00	1,500	240,000	0	Apr 17 04:04 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience